Navigating the Unfamiliar Waters of Clinical Trials
If you feel that finding information about clinical trials is similar to the experience of sailing through deep unfamiliar waters while facing the stiff headwinds of incomprehension, you are not alone. What follows is your “message in a bottle” to guide you to safe port.
Participation in a clinical trial is strictly voluntary. Once enrolled, you can withdraw at anytime. It is a requirement to sign an “informed consent” document explaining the risks and potential benefits of the trial.
The beneficiaries of clinical trials are not just medical researchers but also you, the patient, due to early access to additional treatment options that would not otherwise be available.
To find a clinical trial that you may wish to participate in, please visit ClinicalTrials.gov.
ClinicalTrials.gov is a practical, easy to use, interactive government website that lets you search, navigate and query a large database of clinical trials for specific information about a trial such as location, purpose, eligibility, and should be used in conjunction with advice from your doctor or other health care professionals.
If you specifically wish to take part in a EpicentRx trial, see our list of trials below, or add EpicentRx to the search function on the ClinicalTrials.gov home page.
EpicentRx Clinical Trials
Click on a study for further information about each trial.
Study: A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer
Condition: Colorectal Neoplasms
Interventions: Drug: RRx-001; Drug: Regorafenib
Study: A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab
Conditions: Malignant Solid Tumor; Lymphoma
Interventions: Drug: RRx-001; Drug: Nivolumab
Study: RRx-001 in Small, Non-small Cell Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens
Conditions: Small Cell Lung Carcinoma;Carcinoma, Non-Small-Cell Lung, Ovarian Cancer; Neuroendocrine Tumors
Interventions: Drug: RRx-001; Drug: Cisplatin/carboplatin plus albumin (nab-paclitaxel or Abraxane); Drug: cisplatin/carboplatin plus etoposide
Study: Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases
Conditions: Brain Metastases
Interventions: Drug: RRx-001 + WBRT
Study: A Phase I, Multiple Ascending Dose Study to Assess the Safety and Tolerability of RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)
Conditions: Malignant Solid Tumor
Interventions: Drug: RRx-001; Drug: Irinotecan
Study: Phase 1 Two Part Dose Escalation Trial of RRx-001 + Radiation + Temozolomide and RRx-001 + Temozolomide Post-RT In Newly Diagnosed Glioblastoma and Anaplastic Gliomas
Conditions: Glioblastoma and Anaplastic Gliomas
Interventions: RRx-001 + Radiation + Temozolomide
Clinical Trials FAQ